OraSure Reports Mixed Q2 2026 Results with Strategic Regulatory Wins
Event summary
- Q2 revenue of $30.6M, up 9.7% sequentially but down 2% YoY.
- GAAP net income of $6.2M vs. a loss of $19.7M in Q2 2025.
- FDA cleared Colli-Pee™•Dx urine collection device for STI testing.
- FDA granted EUA for OraQuick™ Ebola 2.0 Rapid Antigen Test.
- $22M reduction in contingent consideration liability from FDA feedback.
The big picture
OraSure's Q2 results reflect a mixed bag of sequential growth and YoY declines, underscored by key regulatory wins in decentralized diagnostics. The company's strategy to expand accessible healthcare aligns with broader industry trends toward at-home testing solutions. With a strong cash position and recent FDA clearances, OraSure is positioning itself for targeted growth initiatives amid competitive pressures in the diagnostic space.
What we're watching
- Regulatory Execution
- Whether OraSure can sustain its FDA approval momentum with the InteliQuick™ CT/NG submission after withdrawing the current filing.
- Revenue Diversification
- How the company will balance core business stability with growth initiatives in decentralized diagnostics.
- Financial Flexibility
- The pace at which OraSure deploys its $161M cash position for strategic acquisitions or innovation scaling.
Related topics